Vaccines for the 21st century : a tool for decisionmaking /
| Corporate Author: | |
|---|---|
| Other Authors: | , , |
| Format: | Book |
| Language: | English |
| Published: |
Washington, D.C. :
National Academy Press,
[2000]
|
| Subjects: |
Table of Contents:
- Introduction
- Considerations related to the model and the study
- Organization of the report
- Progess in vaccine development
- Priorities of the IOM Committee in 1985
- Litigation as a barrier to vaccine development
- A case study of success
- Advances in biotechnology and molecular immunology and new opportunities for vaccines
- Considerations of candidate vaccines
- Exclusion criteria
- Additional considerations for inclusion
- Overview of analytic approach and results
- A cost-effectiveness approach
- Model overview
- Examples: hypothetical vaccine X
- Results
- Review of the analytic model
- Unit of analysis
- Implementing the analysis
- Calculation of health benefits
- Cost factors
- Vaccine efficacy and utilization
- Cost-effectiveness ratios
- Ethical considerations and caveats
- Ethical and value judgments built into the model
- Considerations of justice
- Observations
- The funding of research
- Neglected opportunities for vaccine R&D
- Qualitative judgments
- Vaccine program concerns
- Appendixes
- Borrelia burgdorferi
- Chlamydia
- Coccidioides Immitis
- Cytomegalovirus
- Enterotoxigenic E. coli
- Epstein-Barr virus
- Helicobacter pylori
- Hepatitis C
- Herpes simplex virus
- Histoplasma capsulatum
- Human papillomavirus
- Influenza A and B
- Insulin-dependent diabetes mellitus
- Melanoma
- Multiple sclerosis
- Mycobacterium tuberculosis
- Neisseria gonorrhea
- Neisseria meningitidis
- Parainfluenza virus
- Respiratory syncytial virus
- Rheumatoid arthritis
- Rotavirus
- Shigella
- Streptococcus, group A
- Streptococcus, group B
- Streptococcus pneumoniae
- Information on accessing electronic spreadsheets
- Summary of workshops
- Questions posed to outside experts and list of responders.